SLOTS-CAPITAL
11.6.2021 11:24:04 CEST | Business Wire | Pressemeddelelse
Slots Capital, et af de mest populære online casinoer i verden, er nu tilgængelig for flere spillere end nogensinde før, når de for første gang lander i flere nye lande.
Det betyder, at spillere i Belgien, Rumænien, Grækenland, Danmark, Finland, Irland, Letland og Luxembourg nu kan nyde godt af den førsteklasses online casinooplevelse, som Slots Capital tilbyder.
Hvis du elsker spillemaskiner, så er Slots Capital stedet, hvor du kan vælge mellem mere end 300 spil fra kendte udviklere såsom Rival, Saucify, Dragon og Qora.
Faktisk har vi for nylig styrket vores spillemaskiner og bordspil-lobby med titler fra eftertragtede spilstudier, herunder Rival Gaming, Dragon Gaming, Saucify Gaming og Qora Gaming.
Vi vil også tilføje spillemaskiner fra Arrow's Edge i de kommende uger, men i mellemtiden kan spillere prøve de nyeste titler ved at udforske vores lobby, som inkluderer:
- Dead Beats
- Irish Wishes
- Lucky Macau
- Panda Playtime
- Sands of Space
- Twin Dragons
- Viking Victory
- Win Another Day
- Wrath of Medusa
- Yeti Hunt i3D
Slots Capital er ikke kun kendt for at være den bedste destination for spillemaskiner, vores spillere elsker også de daglige bonusser, bonusser uden indbetaling, superhurtige udbetalinger og 24/7 kundesupport.
Vi er mobilvenlige, hvilket betyder, at du kan tilgå alle vores spillemaskiner samt vores generøse bonusser, betalingsmuligheder og kundesupport fra din smartphone eller tablet.
Hos Slots Capital vil vi gerne byde nye spillere velkommen med en enorm generøs indbetalingsmatchbonus; når du indbetaler 150 kr., tilføjer vi 450 kr. til din saldo, hvilket giver dig 600 kr. at spille med totalt.
Hvis ikke det var nok, tilbyder vi også match-bonusser på dine næste tre indbetalinger, hvor du kan modtage 250 %, 300 % og 400 %!
Sharon Kane, Slots Capital , udtalte: "Vi er så begejstrede over at have lanceret Slots Capital på otte nye markeder, og for at spillere kan nyde en af de bedste online casinooplevelser på markedet.
Vi har for nylig føjet en række efterspurgte udbydere til vores allerede imponerende lobby, hvilket viser vores engagement til at tilbyde spillere det bredest-mulige udvalg af spillemaskiner at vælge imellem.
Hvis du ikke allerede har spillet hos Slots Capital, hvad venter du så på - udnyt vores gavmilde velkomsttilbud og kom og se, hvad alle taler om."
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20210611005178/da/
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum